跳轉至內容
Merck
全部照片(1)

重要文件

SML2482

Sigma-Aldrich

替格瑞洛

≥98% (HPLC)

同義詞:

替格瑞洛, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-二氟苯基)环丙基]氨基}-5­(丙硫基)-3H-[1,2,3]-三唑并[4,5-d]吡啶基-3-yl]-5-(2-羟基乙氧基)环戊烷-1,2-二醇, (1 S ,2 S ,3 R ,5 S )-3-[7-{[(1 R ,2 S )-2-(3,4-二氟苯基)环丙基] 氨基 }-5-(丙基砜基)-3 H - [1,2,3] 三唑 [4,5- d 嘧啶-3-基]-5-(2-羟乙氧基)-1,2-环戊二醇

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C23H28F2N6O4S
CAS號碼:
分子量::
522.57
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D -55 to -65°, c = 0.2 in methanol

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

FC1=C(F)C=C([C@]2([H])C[C@@]2([H])NC3=NC(SCCC)=NC4=C3N=NN4[C@]5([H])C[C@H](OCCO)[C@@H](O)[C@H]5O)C=C1

InChI

1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

InChI 密鑰

OEKWJQXRCDYSHL-FNOIDJSQSA-N

基因資訊

human ... P2RY12(64805)

尋找類似的產品? 前往 產品比較指南

一般說明

替格瑞洛(AZD6140)是一种环戊基三唑嘧啶。

生化/生理作用

替格瑞洛是一种抗血栓形成抗血小板药物,直接和可逆地竞争性抑制腺嘌呤受体P2Y12受体发挥作用。可用于治疗急性冠状动脉综合征患者。也可改善内皮功能。替格瑞洛可抑制人红细胞摄取腺苷,促进人红细胞释放腺苷三磷酸(ATP)。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor
José C Nicolau et al.
Expert opinion on pharmacotherapy, 19(9), 1013-1019 (2018-06-13)
Cardiovascular disease (CVD) is the main cause of death in the world. Coronary artery disease (CAD) is the most common form of CVD presentation, but the prevalence of peripheral artery disease (PAD) is increasing. Patients with polyvascular disease comprise a
Riyaad Aungraheeta et al.
Blood, 128(23), 2717-2728 (2016-10-04)
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize its molecular mechanism of action. Initial studies showed that ticagrelor promoted

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務